Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to analyze the multi-omics results between uterine cervical adenocarcinoma patients with and without human papillomavirus (HPV) infections. The multi-omics profiles include genome wide association study (GWAS), whole exome sequencing, analysis of transcriptomics and metabolomics. The HPV integration status is interpreted by GWAS. A comprehensive multi-omics will reveal the role of HPV integration in the molecular mechanism of tumorigenesis and prognosis of uterine cervical adenocarcinoma.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with HPV integration | The HPV integration status will be checked by GWAS. |
| |
| Patients without HPV integration | The HPV integration status will be checked by GWAS. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| A multi-omics analysis | Combination Product | A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Frequencies of somatic driving mutations | The differences of frequencies of somatic driving mutations will be compared between patients with and without HPV integration. | Two years |
| Measure | Description | Time Frame |
|---|---|---|
| Frequencies of alteration of RNA expression | The alteration of patterns of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients with and without HPV integration. | Two years |
| Frequencies of alteration of protein expression and signal pathway |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
All patients confirmed primary adenocarcinoma of the uterine cervix
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lei Li, M.D. | Contact | 13911988831 | 86 | lileigh@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Lei Li, M.D. | Peking Union Medical College Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lei Li | Recruiting | Beijing | Beijing Municipality | 100730 | China |
All data will be available to all researchers.
All data will be available to all researchers once related papers have been accepted publicly, and will be available for ever.
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D063646 | Carcinogenesis |
| ID | Term |
|---|---|
| D009385 | Neoplastic Processes |
| D009369 | Neoplasms |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
An 8 ml peripheral venous blood, and 50 μL cancer tissue and tissue adjacent to cancer will be collected from eligible patients.
The alteration of patterns of protein expression and signal pathway will be compared between patients with and without HPV integration. |
| Two years |
| Progression-free survival | Progression-free survival between patients with differential expressed multi-omics will be compared. | Five years |